NUVA Stock Recent News

SAN DIEGO , Feb. 27, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that NuVasive management will participate in upcoming investor conferences and will be joined by Globus Medical management to discuss the two companies' recent merger announcement and other business topics: Citi 2023 Healthcare Services, MedTech, Tools and HCIT Conference, March 2, 2023 in New York City. The fireside chat will begin at 9:30 a.m.

Inflationary costs, supply chain disruptions, volatility in foreign exchange rates and the persistent COVID-led impact hurt NuVasive's (NUVA) Q4 revenues.

NuVasive, Inc. (NASDAQ:NUVA ) Q4 2022 Earnings Conference Call February 22, 2023 4:30 PM ET Company Participants Juliet Cunningham - VP, IR Christopher Barry - CEO & Director Matthew Harbaugh - EVP & CFO Conference Call Participants Matthew Miksic - Barclays Bank Shagun Chadha - RBC Capital Markets Eric Anderson - Cowen and Company Joseph Conway - Needham & Company Andrew Ranieri - Morgan Stanley Lilia-Celine Lozada - JPMorgan Chase & Co. Vikramjeet Chopra - Wells Fargo Securities Operator Good day, ladies and gentlemen, and welcome to the NuVasive Fourth Quarter and Full Year 2022 Earnings Conference Call. I would now like to introduce your host for today's call, Ms.

NuVasive (NUVA) delivered earnings and revenue surprises of -12.24% and 1.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Globus and NuVasive agreed to merge in a deal that will see Globus acquire its spinal surgery rival for 0.75 shares of GMED per NUVA share (or $3.1B). Globus shares sold off sharply, as the Street clearly isn't sold on the advantages of the deal and/or Globus management's ability to fix NUVA's longstanding margin issues.

The implied price for NuVasive under terms of the deal is $57.72 a share.

Globus Medical GMED, -1.18% said Thursday it will pay 0.75 a share of its stock for each share of NuVasive NUVA, -2.41% stock in a deal that values NuVasive at about $3.1 billion or $57.72 a share. Globus Medical stock is down 12% in premarket trades, while NuVasive stock is rallying 11.9%.

NuVasive (NUVA) believes that its 2022 guidance is appropriately conservative, considering macroeconomic pressures on net sales and operating profit.

NuVasive is a strong medical technology play driven by its revenue growth opportunities in the area of less invasive spine surgery. The company's modern less invasive spine surgery techniques can boost its revenue growth to a significant extent in the long term.

The continued demand for NuVasive's (NUVA) Simplified Cervical Disc is encouraging.